Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The digital revolution looks to be sweeping across different industries, which are now fully embracing technologies around connectivity, big data and artificial intelligence to drive innovation and better outcomes. Health care seems to have come late to this party, but changes are happening as medtech companies make a concerted effort to incorporate the advanced computing capabilities needed to turn devices into smart machines that are constantly learning and adapting. Surgery is one area that will benefit from these smart technologies and Scott Huennekens, CEO of Verb Surgical, tells Medtech Insight how the J&J/Verily joint venture aims to make this happen.
Latest From Innovation
Check out what Verb Surgical CEO Scott Huennekens had to say about innovation in an era of tough medtech competition.
Germany's medtech industry is yet to find out who will hold the political reins for health care and the other ministerial portfolios that influence the market access and innovation support mechanisms for medtech products. Meanwhile, in the run-up to Medica 2017, German manufacturers were reporting both moderate business growth and increasing concern about reimbursement issues and the EU MDR and IVDR, which are making life less predictable for medtech innovators.
The volume of original PMAs coming to US FDA for review is down recently, while panel-track supplement, de novo and 510(k) volumes are up. October, meanwhile, was a relatively light month for novel device approvals, but better-than-average for 510(k) clearances.
Rivals Catching Up To Intuitive Surgical In Fast-Growing, Fast-Innovating Robotic-Assisted Devices Market
The global market for robotically assisted systems (RAS) is expected to reach $5.3bn by 2021, a CAGR of 11.7%. Meddevicetracker expects this hot market, long-dominated by Intuitive Surgical's da Vinci systems, to see rising competition from innovative companies developing robotic systems that are smaller, portable and less costly and offer surgeons innovative features that allow them to perform even more precise and user-friendly, complex surgeries. In this feature, we'll take a closer look at the overall market, highlighting the competitive landscape as well as limiters and growth opportunities. We'll also take a deep dive into RAS systems and their applications. Surgeons of various specialties provide key insights about the pros and cons of different systems.
The CE Marks recorded in October include Abbott's new version of Xience and Medinol's BioNIR drug-eluting coronary stents, plus 18 other devices approved in eight different territories.
The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions each month. This month's edition, covering a long list of device trial updates that occurred between Sept. 24 and Oct. 31, is headlined by Medtronic's APOLLO US pivotal trial of the Intrepid transcatheter mitral valve.
Pear Therapeutics announced US Expedited Access Pathway designation earlier this month for its 510(k)-route reSET-O Prescription Digital Therapeutic for OUD, perhaps providing some insight into the types of products seeking a "substantial equivalence" claim that might, nonetheless, be considered breakthroughs.
Healthcare giant Merck is on a mission to introduce automation to fertility treatment and improve patient outcomes. The German company, already a leader in fertility drugs, aims to expand its market position by delivering innovative device technologies.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.